Page last updated: 2024-09-04

resiquimod and Carcinoma

resiquimod has been researched along with Carcinoma in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Im, SA; Lee, CK; Lee, M; Lee, YR; Park, CS; Song, S1
Anz, D; Bourquin, C; Endres, S; Heidegger, S; Hotz, C; Noerenberg, D; Roetzer, LC; Sandholzer, N; Storch, B; Voelkl, A; Wurzenberger, C1

Other Studies

2 other study(ies) available for resiquimod and Carcinoma

ArticleYear
Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells.
    Archives of pharmacal research, 2014, Volume: 37, Issue:9

    Topics: Animals; Antigens, Differentiation; Antineoplastic Agents; Carcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dendritic Cells; Imidazoles; Immunologic Factors; Macrophages; Male; Mammary Neoplasms, Experimental; Mice, Inbred BALB C; Myeloid Progenitor Cells; Specific Pathogen-Free Organisms; Spleen; Toll-Like Receptor 7; Toll-Like Receptor 8

2014
Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance.
    Cancer research, 2011, Aug-01, Volume: 71, Issue:15

    Topics: Animals; Carcinoma; Cells, Cultured; Colonic Neoplasms; Cytokines; Dendritic Cells; Drug Screening Assays, Antitumor; Female; Imidazoles; Immune Tolerance; Interferon-alpha; Interleukin-1 Receptor-Associated Kinases; Interleukin-12; Interleukin-6; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Toll-Like Receptor 7; Tumor Escape

2011